1 |
B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans.
53
62
|
Warnatz K...Eibel H
|
19666484 |
2009 |
2 |
To switch or not to switch--the opposing roles of TACI in terminal B cell differentiation.
53
62
|
Salzer U...Grimbacher B
|
17171762 |
2007 |
3 |
Immunoglobulin Deficiency and the Unified Airway.
62
|
Makary CA...Lugar P
|
36266110 |
2023 |
4 |
Computational Analysis of Antibody Paratopes for Antibody Sequences in Antibody Libraries.
62
|
Peng HP...Yang AS
|
36346607 |
2023 |
5 |
Bioinformatic Analysis of Natively Paired VH:VL Antibody Repertoires for Antibody Discovery.
62
|
Fahad AS...DeKosky BJ
|
36346608 |
2023 |
6 |
Improvement of Anti-CD36 Antibody Detection via Monoclonal Antibody Immobilization of Platelet Antigens Assay by Using Selected Monoclonal Antibodies.
62
|
Xu X...Fu Y
|
36045061 |
2023 |
7 |
Safety of and antibody response to the BNT162b2 COVID-19 vaccine in adolescents and young adults with underlying disease.
62
|
Shoji K...Miyairi I
|
36152928 |
2023 |
8 |
Depressive symptoms predict antibody titers after a second dose of the SARS-CoV-2 BNT162b2 vaccine among hospital workers in Japan.
62
|
Kaneko H...Tsuboi H
|
36116693 |
2023 |
9 |
A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants.
62
|
Lam JY...Kok KH
|
35275039 |
2022 |
10 |
Post-vaccination SARS-CoV-2 antibody kinetics and protection duration against Omicron in elderly population.
62
|
Dimeglio C...Izopet J
|
36064047 |
2022 |
11 |
A new testing platform using fingerstick blood for quantitative antibody response evaluation after SARS-CoV-2 vaccination.
62
|
Du J...Sha MY
|
34951566 |
2022 |
12 |
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation.
62
|
Wang Q...Ho DD
|
36328002 |
2022 |
13 |
Peptide microarrays coupled to machine learning reveal individual epitopes from human antibody responses with neutralizing capabilities against SARS-CoV-2.
62
|
Hotop SK...Bronstrup M
|
35320064 |
2022 |
14 |
A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses.
62
|
Wang P...Ho DD
|
34836485 |
2022 |
15 |
Bronchiectasis and obstructive lung diseases in primary antibody deficiencies and beyond: update on management and pathomechanisms.
62
|
Hanitsch LG
|
36165423 |
2022 |
16 |
Lung directed antibody gene transfer confers protection against SARS-CoV-2 infection.
62
|
Du Y...Hyde SC
|
35165144 |
2022 |
17 |
Antibody-mediated autoimmune encephalitis evaluated by 18F-DPA714 PET/MRI.
62
|
Shen R...Chen S
|
36267833 |
2022 |
18 |
Comparison of two antibody screening systems for SARS-CoV-2 antibody detection in recovered and vaccinated subjects - test performance and possible indicators for immunity.
62
|
Jonczyk R...Blume C
|
36279696 |
2022 |
19 |
Typical cutaneous small-vessel vasculitis induced by combined injection of antiphosphatidylserine/prothrombin complex antibody and anti-LAMP-2 antibody in normal rats.
62
|
Kawakami T...Ishizu A
|
35876151 |
2022 |
20 |
Anti-PLA2R antibody measured by ELISA predicts the risk of vein thrombosis in patients with primary membranous nephropathy.
62
|
Zhu H...Yang X
|
35380081 |
2022 |
21 |
Behaviour of the model antibody fluid constrained by rigid spherical obstacles: Effects of the obstacle-antibody attraction.
62
|
Hvozd T...Vlachy V
|
36426679 |
2022 |
22 |
Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10.
62
|
Mayer KA...Bohmig GA
|
36382130 |
2022 |
23 |
The effect of the BNT162b2 vaccine on antinuclear antibody and antiphospholipid antibody levels.
62
|
Noureldine HA...Mokhbat JE
|
35978253 |
2022 |
24 |
Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy.
62
|
Shi F...Zhang M
|
35506447 |
2022 |
25 |
"Titer of anti-HBs in health professions trainees: prevalence of antibody coverage in a University of Central Italy".
62
|
Di Giampaolo L...Mangifesta R
|
34166177 |
2022 |
26 |
The Challenging but Imperative Path to Monoclonal Antibody Use Against COVID-19 for a Small Overseas Military Hospital.
62
|
Shirk S...Paz DA
|
33993282 |
2022 |
27 |
Selection of a PD-1 blocking antibody from a novel fully human phage display library.
62
|
Peissert F...Neri D
|
36317676 |
2022 |
28 |
No correlation of neutralizing antibody titers against the Omicron variant after a booster dose of COVID-19 vaccines with subsequent breakthrough Omicron infections among healthcare workers.
62
|
Lee J...Kim SH
|
36223860 |
2022 |
29 |
Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75.
62
|
Cao Y...Wang X
|
36270286 |
2022 |
30 |
Highly mutated monoclonal antibody 3F2 targets a conformational and strain-restricted epitope in human immunodeficiency virus gp41 with significant antibody-dependent cell cytotoxicity.
62
|
DeCotes D...Hicar MD
|
35871426 |
2022 |
31 |
Correction: Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64).
62
|
|
36332930 |
2022 |
32 |
A novel plant-made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS-CoV-2 Omicron variant.
62
|
Jugler C...Chen Q
|
36403203 |
2022 |
33 |
The third inactivated vaccine booster dramatically enhanced SARS-CoV-2 antibody responses and did not influence the profile of prothrombotic antibody.
62
|
Pan Y...Li Y
|
36443279 |
2022 |
34 |
Specific antibody deficiency to pneumococcal polysaccharide in a young adult with recurrent respiratory infections: a case report.
62
|
Ishimaru N...Ohnishi H
|
36382810 |
2022 |
35 |
Specific antibody deficiency: pearls and pitfalls for diagnosis.
62
|
Lawrence MG...Borish L
|
35671934 |
2022 |
36 |
An Expert Opinion/Approach: Clinical Presentations, Diagnostic Considerations, and Therapeutic Options for Gastrointestinal Manifestations of Common Variable Immune Deficiency.
62
|
Hashash JG...Farraye FA
|
36148549 |
2022 |
37 |
Primary antibody deficiencies represent an underestimated comorbidity in asthma patients: efficacy of immunoglobulin replacement therapy in asthma control.
62
|
Vivarelli E...Vultaggio A
|
36282045 |
2022 |
38 |
Novel CD81 Mutations in a Chinese Patient Led to IgA Nephropathy and Impaired BCR Signaling.
62
|
Yang L...Zhao X
|
35849269 |
2022 |
39 |
Antibody Response to HML-2 May Be Protective in Amyotrophic Lateral Sclerosis.
62
|
Garcia-Montojo M...Nath A
|
36053951 |
2022 |
40 |
Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis.
62
|
Schmierer K...Boschert U
|
35672923 |
2022 |
41 |
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
62
|
Valanparambil RM...Ahmed R
|
35759727 |
2022 |
42 |
Bipolar silica nanochannel array confined electrochemiluminescence for ultrasensitive detection of SARS-CoV-2 antibody.
62
|
Gong J...Liu J
|
35870336 |
2022 |
43 |
Narrative Review of Anti-CD3 Antibody and Anti-CD20 Antibody: Immunotherapeutic Strategies to Treat and Prevent Type 1 Diabetes.
62
|
Kashalikar P...Bhonde R
|
36415095 |
2022 |
44 |
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.
62
|
D'Souza A...Kumar S
|
36029527 |
2022 |
45 |
Efficacy of venetoclax plus anti-CD38 monoclonal antibody-containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody.
62
|
Regidor BS...Berenson JR
|
36367357 |
2022 |
46 |
Anti-GD2 antibody for radiopharmaceutical imaging of osteosarcoma.
62
|
Fu Y...Sgouros G
|
35809088 |
2022 |
47 |
T cell deficiency precipitates antibody evasion and emergence of neurovirulent polyomavirus.
62
|
Lauver MD...Lukacher AE
|
36341713 |
2022 |
48 |
Clinical Outcomes, Immunogenicity, and Safety of BNT162b2 Vaccine in Primary Antibody Deficiency.
62
|
Milota T...Kalina T
|
36379409 |
2022 |
49 |
Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals.
62
|
Ainsua-Enrich E...Carrillo J
|
36320330 |
2022 |
50 |
Changes in anti-MDA5 antibody titres and serum cytokine levels before and after diagnosis of anti-MDA5 antibody-positive dermatomyositis.
62
|
Kogami M...Tamura N
|
36326436 |
2022 |